ProKidney Corp. (PROK)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 893,000 1075%
- Net income
- -68,986,000
- Operating income
- -165,007,000
- R&D expense
- 114,123,000
Growth and profitability
- Operating margin
- -18,477.83
- Net margin
- -7,725.20
- Return on assets
- -20.56
- Free cash flow margin
- -15,152.63
Balance sheet
- Total assets
- 335,574,000
- Total liabilities
- 34,781,000
- Shareholders' equity
- -1,011,197,000
- Cash and equivalents
- 108,537,000
- Current ratio
- 9.13
Cash flow and ratios
- Operating cash flow
- -120,117,000
- Free cash flow
- -135,313,000
Shareholder returns
- Share buybacks
- 0
Company information
- Headquarters
- Winston-Salem, NC
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Biological Products, (no Diagnostic Substances)
Fiscal year end: · Source: SEC EDGAR
ProKidney Corp. trades on NASDAQ under the ticker symbol PROK. This page brings together its price chart, company profile, key financial figures and technical indicators.